Clinical Trials Browser

Phase 1/2 × INDUSTRY × CB-839 × Clear all

NCT02771626 2023-03-17

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Terminated

118 enrolled 18 charts

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT03965845 2022-09-19

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Phase 1/2 Completed

Other solid neoplasmThoracic

Solid Tumors

NCT03875313 2022-02-17

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Phase 1/2 Terminated

33 enrolled 14 charts

BreastGastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms